New hope for tough lung cancers: pill targets rare genetic driver
NCT ID NCT04395677
Summary
This study is testing a new oral medication called AB-106 for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1 fusion. The trial aims to find the best dose and see how safe and effective the drug is for 173 patients, including those who have and have not had a similar prior treatment. Patients take a daily pill and are monitored to see if their tumors shrink or stop growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.